Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2 [10]

Leukemia

Volumn 22, Issue 2, 2008, Pages 445-447

  Shukla, S ^a   Sauna, Z E ^a   Ambudkar, S V ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; CELL EXTRACT; DOXORUBICIN; GLYCOPROTEIN P; IMATINIB; IODINE 125; PRAZOSIN; PROTEIN TYROSINE KINASE INHIBITOR; VANADIC ACID;

ASSAY; BINDING SITE; CHRONIC MYELOID LEUKEMIA; CROSS LINKING; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; DRUG TRANSPORT; HUMAN; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; LETTER; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION;

EID: 39149114742     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404897     Document Type: Letter

References (13)

1. Rumpold H, Wolf AM, Gruenewald K, Gastl G, Gunsilius E, Wolf D. RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 2005; 33: 767-775.
2. Widmer N, Rumpold H, Untergasser G, Fayet A, Buclin T, Decosterd LA. Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels. Leukemia 2007: 21: 1561-1562.
3. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401-408.
4. Ferrao PT, Frost MJ, Siah SP, Ashman LK. Overexpression of P-glycoprotein, in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. Blood 2003; 102: 4499-4503.
5. Zong Y, Zhou S, Sorrentino-BP. Reply to 'Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels' by Widmer et al. Leukemia 2007; 21: 1562-1563.
6. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-1942.
7. Sauna ZE, Ambudkar SV. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein: The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J Biol Chem 2001; 276: 11653-11661.
8. Shukla S, Robey RW, Bates SE, Ambudkar SV. The calcium channel blockers, 1,4-dihydropyridines; are substrates of the multidrug resistance-linked ABC drug transporter, ABCG2. Biochemistry 2006; 45: 8940-8951.
9. Ozvegy-Laczka C, Hegedus T, Várady G, Ujhelly O, Schuetz JD, Váradi A et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004; 65: 1485-1495.
10. Houghton PJ; Germain GS, Harwood FC, Schuetz JD, Stewah CF, Buchduriger E et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res 2004; 64: 2333-2337.
11. Brendel C, Soharenberg C, Dohse M, Robey RW, Bates SE, Shukla S et al Imatinib mesylate and milotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007; 21: 1267-1275.
12. Burger H, vari Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G et al Imatinib mesylate (ST1571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 2004; 104; 2940-2942.
13. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2007; doi:10.1038/sj.clpt.6100268. [E-pub ahead of print].